Hughes Eric A 4
4 · TEVA PHARMACEUTICAL INDUSTRIES LTD · Filed Mar 9, 2026
Research Summary
AI-generated summary of this filing
TEVA EVP Eric Hughes Sells 9,533 Shares to Cover Taxes
What Happened
Eric A. Hughes, Executive Vice President, Global R&D and Chief Medical Officer of TEVA Pharmaceutical (TEVA), had 19,654 restricted share units (RSUs) vest on March 5, 2026. Those RSUs converted into 19,654 ordinary shares (reported as a derivative conversion). To cover tax withholding related to the vesting, Hughes sold 9,533 of those shares in open-market transactions for aggregate proceeds of $301,895 (weighted average price $31.67; individual sale prices ranged $31.26–$32.34). Net shares delivered to Hughes after the tax sale were 10,121 shares (19,654 vested − 9,533 sold).
Key Details
- Transaction date: March 5, 2026; Form 4 filed March 9, 2026 (timely).
- Sale: 9,533 shares sold, weighted avg price $31.67, total proceeds $301,895 (prices ranged $31.26–$32.34).
- Vesting/conversion: 19,654 RSUs converted into ordinary shares (reported as derivative exercise/conversion).
- Net shares received from vesting after tax-sale: 10,121 shares.
- Notable footnotes: sale executed under a Rule 10b5-1 trading plan adopted Nov 10, 2025 (F3); the sale represented shares required to be sold to cover tax withholding on vested RSUs (F4, F6). Each ordinary share may be represented by an ADS (F1).
- Shares owned after transaction: not specified in the filing.
Context
- This was not a market-timing purchase; it was a routine vesting of RSUs with a portion sold to cover taxes (common practice and not necessarily a signal about company prospects).
- The filing shows conversion of RSUs (derivative exercise/conversion code M) and an open-market sale (code S). The sale was executed under a pre-established 10b5-1 plan, which schedules trades irrespective of short-term company developments.
Insider Transaction Report
- Exercise/Conversion
Ordinary Shares
[F1][F2]2026-03-05+19,654→ 117,244 total - Sale
Ordinary Shares
[F1][F3][F4][F5]2026-03-05$31.67/sh−9,533$301,895→ 107,711 total - Exercise/Conversion
Restricted Share Units
[F2][F6][F1]2026-03-05−19,654→ 58,962 total→ Ordinary Shares (19,654 underlying)
Footnotes (6)
- [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- [F2]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- [F3]The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025.
- [F4]Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.26 to $32.34, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F6]Restricted share units were granted on March 5, 2025, with 19,654 vested on March 5, 2026, and 19,654 vesting on each of March 5, 2027, March 5, 2028 and March 5, 2029.